RDY Dr Reddys Laboratories Ltd featured news, full reports, and detailed charts
Dr Reddys Laboratories Ltd (RDY) Wrap Up:
Dr. Reddy?s Laboratories Limited, together with its subsidiaries, operates as a pharmaceutical company. It produces finished dosage forms, active pharmaceutical ingredients and intermediates, and biotechnology products. The company also conducts research in the areas of cancer, diabetes, cardiovascular, inflammation, and bacterial infection. In addition, it involves in the contract manufacture generic prescription and over-the-counter products for branded and generic companies in the United States. The company primarily focuses on therapeutic categories of cardiovascular, diabetes management, gastro-intestinal, and pain management. It markets its products in India, the United States, Europe, and the Russian Federation. The company has a co-development and commercialization agreement with Rheoscience A/S for the development and commercialization of Balaglitazone/DRF 2593, a partial PPAR-gamma agonist for the treatment of type 2 diabetes; an agreement with ClinTec International for the development of an anti-cancer compound, DRF 1042; collaboration with the National Cancer Institute in Maryland; and an agreement with Argenta Discovery Limited for the joint development and commercialization of a novel approach to the treatment of chronic obstructive pulmonary disease. It also has an agreement with 7TM Pharma for drug discovery collaboration on selected drug targets; and an agreement with GlaxoSmithKline plc to develop and market pharmaceuticals for the treatment of cardiovascular disease, diabetes, oncology, gastroenterology, and pain management. Dr. Reddy?s Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.Dr Reddys Laboratories Ltd (RDY:NYSE)
Snapshot of Dr Reddys Laboratories Ltd (RDY)
|
OPEN
$23.79
|
PREVIOUS CLOSE
$23.45
|
|
|
DAY HIGH
$24.10
|
DAY LOW
$23.71
|
|
|
52 WEEK HIGH
11/11/09 - $24.76
|
52 WEEK LOW
03/9/09 - $7.27
|
|
|
MARKET CAP
4.0B
|
AVERAGE VOLUME 3 mo
442.4K
|
|
|
DILUTED EPS TTM
$-0.27
|
SHARES OUTSTANDING
168.4M
|
|
|
EX-DATE
07/2/09
|
P/E TTM
NM
|
|
|
DIVIDEND
$0.13
|
DIVIDEND YIELD
0.54%
|
|
| K = Thousands M = Millions B = Billions | ||
RDY Top Compensated Officers
Executives, Board Directors
Key developments for Dr Reddys Laboratories Ltd (RDY)
Dr. Reddy's Laboratories Ltd. reported earnings results for the second quarter ended September 2009. For the quarter, the company reported a 106% growth in its net profit at INR 2,173 million compared to INR 1,052 million in the corresponding quarter a year ago. Revenues, including forex gain of INR 240 million, during the quarter touched INR 18,368 million against INR 16,151 million, reflecting an increase of 14%. EPS stood at INR 12 against INR 6 in same period of last year. Revenues from the rest of Europe grew 29% to INR 654 million. The growth is largely contributed by UK with sales of INR 436 million, while revenues in India stood at INR 2,500 million, from INR 2,200 million, representing a growth of 13% led by key brands Omez, Omez-DSR and Razo.
Dr. Reddy's Laboratories Ltd. reported standalone earnings results for the quarter ended September 2009. The company’s' standalone net profit for the quarter ended September 2009 more than doubled to INR 1,970 million from INR 910 million in the same period last year. Its income was up 16% to INR 10,730 million from INR 9,220 million in the year ago period.
Dr. Reddy's Laboratories Ltd. announced unaudited financial results for the second quarter and half year ended September 30, 2009. For the quarter, the company has reported profit before income tax of INR 2.8 billion against INR 1.3 billion and results from operating activities of INR 2.5 billion against INR 1.8 billion reported in the same period last year. EBITDA was at INR 3.8 billion against INR 2.5 billion, representing a growth of 51%. For the first half year, the company has reported EBITDA of INR 8.2 billion a year on year growth of 70% and consolidated revenues increased 17% to INR 36.6 billion. Capital expenditure for the period is at INR 1.4 billion.
RDY Competitors
| Company | Last | Change |
| Millipore Corp | $67.73 USD | -0.22 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | RDY | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 2.6x |
|
| Price/Book | 4.3x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 2.3x |
|
|
RDY |
||
RDY transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||